Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
334 participants
INTERVENTIONAL
2011-06-30
2012-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of ESBA105 Eye Drops in Healthy Subjects
NCT00671619
A Study of AL-38583 Ophthalmic Solution 0.05%, 0.010% Versus AL-38583 Vehicle for Dry Eye
NCT00893139
ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease
NCT04899518
Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome
NCT00025818
Study of VVN001 Ophthalmic Solution in Dry Eye Disease
NCT04556838
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ESBA105
ESBA105 ophthalmic solution, 1 drop in each eye 3 times per day for 4 weeks
ESBA105 ophthalmic solution
Vehicle
ESBA105 vehicle, 1 drop in each eye 3 times per day for 4 weeks
ESBA105 vehicle
Inactive ingredients used as Run-In and placebo comparator
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ESBA105 ophthalmic solution
ESBA105 vehicle
Inactive ingredients used as Run-In and placebo comparator
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Use of artificial tears, gels, lubricants, or re-wetting drops on a regular basis.
* Experience persistent ocular discomfort.
Exclusion Criteria
* Severe Sjogren's Syndrome.
* History of corneal surgery including refractive surgeries.
* Intraocular surgery within 6 months of Visit 1.
* Intraocular or periocular injection within 6 months of Visit 1.
* Lid function abnormalities.
* Use of steroids, tetracycline, doxycycline, etc., within 30 days of Visit 1.
* Any acute infectious or non-infectious ocular condition of the anterior or posterior segments in either eye within 30 days of Visit 1.
* Diseases/conditions of ocular surface associated with clinically significant scarring/destruction of conjunctiva/cornea.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alcon Research
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Contact Alcon Call Center for Trial Locations
Fort Worth, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C-10-079
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.